Efficacy and Safety of DPP-4 Inhibitors and Metformin Combinations in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis

References

• American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2009;32(Supplement_1):S62–7. doi:10.2337/dc09-S062
   PubMed Web of Science ®Google Scholar
• Diabetes Facts & figures. Available from: https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html. Accessed August 23, 2022.
   Google Scholar
• Misra A, Gopalan H, Jayawardena R, et al. Diabetes in developing countries. J Diabetes. 2019;11(7):522–539. doi:10.1111/1753-0407.12913
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2022 abridged for primary care providers. Clin Diabetes. 2022;40(1):10–38. doi:10.2337/cd22-as01
   PubMedGoogle Scholar
• Caturano A, Galiero R, Pafundi PC. Metformin for Type 2 Diabetes. JAMA. 2019;322(13):1312. doi:10.1001/jama.2019.11489
   PubMedGoogle Scholar
• Scheen AJ, Charpentier G, Östgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26(7):540–549. doi:10.1002/dmrr.1114
   PubMed Web of Science ®Google Scholar
• Luna B, Feinglos MN. Oral Agents in the Management of Type 2 Diabetes Mellitus. AFP. 2001;63:1747.
   Google Scholar
• Nistala R, Savin V. Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. Am J Physiol Renal Physiol. 2017;312:F661–70.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705. doi:10.1016/S0140-6736(06)69705-5
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Clinical Use of DPP-4 Inhibitors. Front Endocrinol. 2019;10:389. doi:10.3389/fendo.2019.00389
   PubMed Web of Science ®Google Scholar
• Makrilakis K. The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect. Int J Environ Res Public Health. 2019;16:E2720.
   Web of Science ®Google Scholar
• Ahrén B. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag. 2008;4:383–394. doi:10.2147/VHRM.S1944
   PubMedGoogle Scholar
• Herman GA, Bergman A, Yi B, et al. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006;22(10):1939–1947. doi:10.1185/030079906X132587
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm - 2017 Executive Summary. Endocr Pract. 2017;23(2):207–238. doi:10.4158/EP161682.CS
   PubMed Web of Science ®Google Scholar
• Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316(3):313–324. doi:10.1001/jama.2016.9400
   PubMed Web of Science ®Google Scholar
• Ge L, Tang Y, Zhang Q-N, et al. A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer. Oncotarget. 2017;8(35):59539–59551. doi:10.18632/oncotarget.19102
   PubMedGoogle Scholar
• Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.557
   PubMed Web of Science ®Google Scholar
• Yang W, Pan CY, Tou C, et al. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabet Res Clin Pract. 2011;94(2):217–224. doi:10.1016/j.diabres.2011.07.035
   Web of Science ®Google Scholar
• Pfützner A, Paz-Pacheco E, Allen E, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011;13(6):567–576. doi:10.1111/j.1463-1326.2011.01385.x
   PubMed Web of Science ®Google Scholar
• Phillips P, Karrasch J, Scott R, et al. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care. 2003;26(2):269–273. doi:10.2337/diacare.26.2.269
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Naditch L; Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care. 2001;24(6):989–994. doi:10.2337/diacare.24.6.989
   PubMed Web of Science ®Google Scholar
• Gu T, Ma J, Zhang Q, et al. Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial. Diabetes Obes Metab. 2019;21(4):939–948. doi:10.1111/dom.13605
   Web of Science ®Google Scholar
• Du J, Liang L, Fang H, et al. Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: results of a Phase IV open-label randomized controlled study (the SMART study). Diabetes Obes Metab. 2017;19(11):1513–1520. doi:10.1111/dom.12942
   Web of Science ®Google Scholar
• Van Gaal L, Maislos M, Schernthaner G, et al. Miglitol combined with metformin improves glycaemic control in type 2 diabetes. Diabetes Obes Metab. 2001;3(5):326–331. doi:10.1046/j.1463-1326.2001.00141.x
   Web of Science ®Google Scholar
• Dou J, Ma J, Liu J, et al. Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: results from the START study, a multicentre, randomized, double-blind, active-controlled, Phase 3 trial. Diabetes Obes Metab. 2018;20(3):590–598. doi:10.1111/dom.13117
   Web of Science ®Google Scholar
• Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27(1):141–147. doi:10.2337/diacare.27.1.141
   PubMed Web of Science ®Google Scholar
• Wang J-S, Huang C-N, Hung Y-J, et al. Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. Diabet Res Clin Pract. 2013;102(1):16–24. doi:10.1016/j.diabres.2013.08.001
   PubMed Web of Science ®Google Scholar
• Cai X-L, Chen Y-L, Zhao -J-J, et al. Efficacy and safety of avandamet or uptitrated metformin treatment in patients with type 2 diabetes inadequately controlled with metformin alone: a multicenter, randomized, controlled trial. Chin Med J. 2015;128(10):1279–1287. doi:10.4103/0366-6999.156735
   Web of Science ®Google Scholar
• Rosenstock J, Rood J, Cobitz A, et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2006;8(6):650–660. doi:10.1111/j.1463-1326.2006.00659.x
   PubMed Web of Science ®Google Scholar
• Oh TJ, Yu JM, Min KW, et al. Efficacy and safety of voglibose plus metformin in patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab J. 2019;43(3):276–286. doi:10.4093/dmj.2018.0051
   PubMed Web of Science ®Google Scholar
• Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22(1):119–124. doi:10.2337/diacare.22.1.119
   PubMed Web of Science ®Google Scholar
• Marre M, Van Gaal L, Usadel K-H, et al. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab. 2002;4(3):177–186. doi:10.1046/j.1463-1326.2002.00196.x
   Web of Science ®Google Scholar
• Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23(11):1660–1665. doi:10.2337/diacare.23.11.1660
   PubMed Web of Science ®Google Scholar
• Raskin P, Lewin A, Reinhardt R, et al. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet. Diabetes Obes Metab. 2009;11(9):865–873. doi:10.1111/j.1463-1326.2009.01062.x
   Web of Science ®Google Scholar
• Lewin A, Lipetz R, Wu J, et al. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study. Clin Ther. 2007;29(5):844–855. doi:10.1016/j.clinthera.2007.05.013
   Web of Science ®Google Scholar
• Jin S-M, Park C-Y, Cho YM, et al. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes Metab. 2015;17(6):599–602. doi:10.1111/dom.12435
   Web of Science ®Google Scholar
• Wang J-S, Lee I-T, Lee W-J, et al. Glycemic excursions are positively associated with changes in duration of asymptomatic hypoglycemia after treatment intensification in patients with type 2 diabetes. Diabet Res Clin Pract. 2016;113:108–115. doi:10.1016/j.diabres.2015.12.010
   PubMed Web of Science ®Google Scholar
• Perez A, Zhao Z, Jacks R, et al. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin. 2009;25(12):2915–2923. doi:10.1185/03007990903350011
   PubMed Web of Science ®Google Scholar
• Kawamori R, Kaku K, Hanafusa T, et al. Effect of combination therapy with repaglinide and metformin hydrochloride on glycemic control in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5(1):72–79. doi:10.1111/jdi.12121
   Web of Science ®Google Scholar
• Wang W, Bu R, Su Q, et al. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy. Expert Opin Pharmacother. 2011;12(18):2791–2799. doi:10.1517/14656566.2011.602341
   PubMed Web of Science ®Google Scholar
• Raskin P, Klaff L, McGill J, et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care. 2003;26(7):2063–2068. doi:10.2337/diacare.26.7.2063
   PubMed Web of Science ®Google Scholar
• Moses R. Repaglinide in combination therapy with metformin in Type 2 diabetes. Exp Clin Endocrinol Diabetes. 1999;107(Suppl 4):S136–139. doi:10.1055/s-0029-1212169
   Google Scholar
• Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887–897. doi:10.1016/S2213-8587(17)30317-0
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Lauring B, Gantz I, et al. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017;33(10):1861–1868. doi:10.1080/03007995.2017.1335638
   PubMed Web of Science ®Google Scholar
• Derosa G, Bonaventura A, Bianchi L, et al. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. Metabolism. 2014;63(7):957–967. doi:10.1016/j.metabol.2014.04.008
   Web of Science ®Google Scholar
• Kim G, Oh S, Jin S-M, et al. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2017;18(12):1179–1186. doi:10.1080/14656566.2017.1353080
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Fogari E, et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. Intern Med. 2007;46(22):1837–1846. doi:10.2169/internalmedicine.46.0320
   Web of Science ®Google Scholar
• González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications. 2009;23(6):376–379. doi:10.1016/j.jdiacomp.2008.09.002
   PubMed Web of Science ®Google Scholar
• Chien -H-H, Chang C-T, Chu N-F, et al. Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. J Chin Med Assoc. 2007;70(11):473–480. doi:10.1016/S1726-4901(08)70044-3
   Google Scholar
• Garber A, Klein E, Bruce S, et al. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2006;8(2):156–163. doi:10.1111/j.1463-1326.2005.00570.x
   Web of Science ®Google Scholar
• Kim H-S, Shin J-A, Lee S-H, et al. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther. 2013;15(10):810–816. doi:10.1089/dia.2013.0038
   Web of Science ®Google Scholar
• Schernthaner G, Durán-Garcia S, Hanefeld M, et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obes Metab. 2015;17(7):630–638. doi:10.1111/dom.12461
   PubMed Web of Science ®Google Scholar
• Garber AJ, Donovan DS, Dandona P, et al. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab. 2003;88(8):3598–3604. doi:10.1210/jc.2002-021225
   PubMed Web of Science ®Google Scholar
• Del Prato S, Camisasca R, Wilson C, et al. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16(12):1239–1246. doi:10.1111/dom.12377
   PubMed Web of Science ®Google Scholar
• Schwarz SL, Gerich JE, Marcellari A, et al. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(8):652–660. doi:10.1111/j.1463-1326.2007.00792.x
   Web of Science ®Google Scholar
• Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin. 2006;22(4):751–759. doi:10.1185/030079906X104786
   PubMed Web of Science ®Google Scholar
• Göke B, Gallwitz B, Eriksson JG, et al. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract. 2013;67(4):307–316. doi:10.1111/ijcp.12119
   PubMed Web of Science ®Google Scholar
• Gerich J, Raskin P, Jean-Louis L, et al. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care. 2005;28:2093–2099.
   PubMed Web of Science ®Google Scholar
• Forst T, Anastassiadis E, Diessel S, et al. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment. Diabetes Metab Res Rev. 2014;30(7):582–589. doi:10.1002/dmrr.2525
   Web of Science ®Google Scholar
• Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010;64(5):562–576. doi:10.1111/j.1742-1241.2010.02353.x
   PubMed Web of Science ®Google Scholar
• Ristic S, Collober‐Maugeais C, Pecher E, et al. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med. 2006;23(7):757–762. doi:10.1111/j.1464-5491.2006.01914.x
   PubMed Web of Science ®Google Scholar
• Göke B, Gallwitz B, Eriksson J, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64(12):1619–1631. doi:10.1111/j.1742-1241.2010.02510.x
   PubMed Web of Science ®Google Scholar
• Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780–789. doi:10.1111/j.1463-1326.2010.01233.x
   PubMed Web of Science ®Google Scholar
• Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13(2):160–168. doi:10.1111/j.1463-1326.2010.01334.x
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205. doi:10.1111/j.1463-1326.2006.00704.x
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157–166. doi:10.1111/j.1463-1326.2008.00994.x
   PubMed Web of Science ®Google Scholar
• Ristic S, Collober-Maugeais C, Cressier F, et al. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. Diabetes Obes Metab. 2007;9(4):506–511. doi:10.1111/j.1463-1326.2006.00632.x
   PubMed Web of Science ®Google Scholar
• Derosa G, Bonaventura A, Bianchi L, et al. Retracted: comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with Type 2 diabetes. Diabet Med. 2014;31(12):1515–1523. doi:10.1111/dme.12499
   Web of Science ®Google Scholar
• Charpentier G, Fleury F, Kabir M, et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med. 2001;18(10):828–834. doi:10.1046/j.1464-5491.2001.00582.x
   PubMed Web of Science ®Google Scholar
• Feinglos M, Dailey G, Cefalu W, et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabet Res Clin Pract. 2005;68(2):167–175. doi:10.1016/j.diabres.2004.09.002
   PubMed Web of Science ®Google Scholar
• Lin S-D, Wang J-S, Hsu S-R, et al. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. J Diabetes Complications. 2011;25(5):332–338. doi:10.1016/j.jdiacomp.2011.06.004
   Web of Science ®Google Scholar
• Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab. 2002;4(3):201–208. doi:10.1046/j.1463-1326.2002.00211.x
   PubMed Web of Science ®Google Scholar
• Home PD, Jones NP, Pocock SJ, et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med. 2007;24(6):626–634. doi:10.1111/j.1464-5491.2007.02160.x
   PubMed Web of Science ®Google Scholar
• Wang M, Lin S, Chen Y, et al. Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin. Diabet Res Clin Pract. 2015;108(3):e67–70. doi:10.1016/j.diabres.2015.02.022
   Web of Science ®Google Scholar
• Rosenstock J, Lewin AJ, Norwood P, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes. Diabet Med. 2011;28(4):464–469. doi:10.1111/j.1464-5491.2010.03181.x
   Web of Science ®Google Scholar
• Shankar RR, Inzucchi SE, Scarabello V, et al. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017;33(10):1853–1860. doi:10.1080/03007995.2017.1335637
   PubMed Web of Science ®Google Scholar
• Filozof C, Gautier J-F. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010;27(8):318–326. doi:10.1111/j.1464-5491.2010.02938.x
   Google Scholar
• Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med. 2010;27(12):1409–1419. doi:10.1111/j.1464-5491.2010.03131.x
   PubMed Web of Science ®Google Scholar
• Ceriello A, Rodbard HW, Battelino T, et al. Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop. Cardiovasc Diabetol. 2023;22(1):277. doi:10.1186/s12933-023-01993-3
   Web of Science ®Google Scholar
• DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649–1655. doi:10.2337/dc08-1984
   PubMed Web of Science ®Google Scholar
• Oh S, Purja S, Shin H, et al. Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Vasc Dis Res. 2022;19(3):14791641221106866. doi:10.1177/14791641221106866
   Web of Science ®Google Scholar
• Valensi P, de Pouvourville G, Benard N, et al. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: the ODYSSEE observational study. Diabetes Metab. 2015;41(3):231–238. doi:10.1016/j.diabet.2015.03.007
   PubMed Web of Science ®Google Scholar
• Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One. 2015;10:e0125879.
   PubMed Web of Science ®Google Scholar
• Wang X, Li X, Qie S, et al. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. Medicine. 2018;97(34):e11946. doi:10.1097/MD.0000000000011946
   Web of Science ®Google Scholar
• Amblee A, Lious D, Fogelfeld L. Combination of saxagliptin and metformin is effective as initial therapy in new-onset type 2 diabetes mellitus with severe hyperglycemia. J Clin Endocrinol Metab. 2016;101(6):2528–2535. doi:10.1210/jc.2015-4097
   PubMed Web of Science ®Google Scholar
• Foroutan N, Muratov S, Levine M. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: systematic review and meta-analysis. Clin Invest Med. 2016;39(2):E48–E62. doi:10.25011/cim.v39i2.26481
   Web of Science ®Google Scholar
• Ou S-M, Shih C-J, Chao P-W, et al. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med. 2015;163(9):663–672. doi:10.7326/M15-0308
   Web of Science ®Google Scholar
• Jeon WK, Kang J, Kim H-S, et al. Correction to: “cardiovascular outcomes comparison of dipeptidyl peptidase-4 inhibitors versus sulfonylurea as add-on therapy for type 2 diabetes mellitus: a meta-analysis. J Lipid Atheroscler. 2022;11(1):89–101. doi:10.12997/jla.2022.11.1.89
   Google Scholar
• Wu S, Chai S, Yang J, et al. Gastrointestinal adverse events of dipeptidyl peptidase 4 inhibitors in type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2017;39(9):1780–1789.e33. doi:10.1016/j.clinthera.2017.07.036
   PubMed Web of Science ®Google Scholar
• Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014;16(1):30–37. doi:10.1111/dom.12174
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–1987. doi:10.2337/dc07-0627
   PubMed Web of Science ®Google Scholar
• Qian D, Zhang T, Zheng P, et al. Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: a network meta-analysis. Diabetes Ther. 2018;9(5):1945–1958. doi:10.1007/s13300-018-0482-5
   Web of Science ®Google Scholar
• Tricco AC, Antony J, Khan PA, et al. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis. BMJ Open. 2014;4(12):e005752. doi:10.1136/bmjopen-2014-005752
   Web of Science ®Google Scholar
• Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110(6):826–833. doi:10.1016/j.amjcard.2012.04.061
   PubMed Web of Science ®Google Scholar
• Engel SS, Golm GT, Shapiro D, et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013;12(1):3. doi:10.1186/1475-2840-12-3
   PubMedGoogle Scholar